Interclean Shanghai

NICE announces launch of a new database to inform the prioritisation of European cancer research

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

EU Begins Revision of Medical Device...

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical...

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI...

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

The National Institute for Health and Clinical Excellence has launched a new database that will help with the identification and prioritisation of future cancer research across Europe.

The Database of Cancer Uncertainties has been developed through the Coordination of Cancer Clinical Practice Guidelines in Europe initiative. CoCanCPG is a consortium of 16 institutional partners from 11 countries and is funded by the European Commission.

Uncertainties around the evidence base used in guideline development are common, indeed, it is rare that all aspects of the management of a condition are supported by high-quality research evidence. In some circumstances, the research has not been done and even where it has been done it may be methodologically flawed or inconclusive.

The cancer uncertainties database will provide a tool to bring these uncertainties together and link into other initiatives such as the UK’s Database of Uncertainties about the Effects of Treatments – DUETs. The uncertainties will be prioritised with input from clinicians, patients, funders and researchers. The prioritised uncertainties can then be promoted to research funders and researchers across the EU. Tracking mechanisms will be developed to avoid duplication of effort and highlight relevant clinical trials that patients can participate in. The co-ordination will help to ensure that the available research funds are spent against identified priorities.

Latest stories

Related stories

EU Begins Revision of Medical Device Regulatory Framework

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical Devices Regulation

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI Rollout in the NHS

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »